These are top 10 stocks traded on the Robinhood UK platform in July
Daron Evans, Chief Financial Officer of Rezolute , Inc. (NASDAQ:RZLT), has recently increased his stake in the company by purchasing common shares valued at approximately $57,700. According to a recent SEC filing, Evans acquired a total of 20,000 shares on March 26, 2025, with purchase prices ranging from $2.88 to $2.89 per share.
The transactions were divided between direct ownership and indirect ownership through a minor child. After these acquisitions, Evans now holds 237,900 shares directly and 23,000 shares indirectly through a minor child. Additionally, other indirect holdings include shares held by his spouse, two other minor children, and PoC Capital LLC.
According to the filing, PoC Capital LLC is a California limited liability company managed by Evans, who disclaims beneficial ownership of these securities except for his pecuniary interest.
In other recent news, Rezolute, Inc. has reported significant developments in its clinical programs and corporate structure. The company announced the addition of Erik Harris to its Board of Directors, bringing his extensive experience in the biopharmaceutical industry to support Rezolute’s strategic goals. On the financial front, Rezolute concluded the quarter with approximately $105 million in cash reserves, which analysts at JMP Securities believe will support the continued development of its lead drug candidate, ersodetug. Meanwhile, JMP Securities raised its price target for Rezolute to $9.00, maintaining a Market Outperform rating, while H.C. Wainwright reiterated a Buy rating with a $14.00 target. The Phase 3 sunRIZE study of ersodetug, targeting congenital hyperinsulinism, has reached a milestone with the Data Monitoring Committee approving the enrollment of infants into the double-blind portion of the trial. The FDA had previously lifted partial clinical holds on the drug, and Rezolute plans to start U.S. patient enrollment soon. The company also released a video presentation detailing a patient’s experience in an ongoing Phase 2 trial, emphasizing the importance of patient perspectives in understanding the impact of its investigational treatments. Investors are encouraged to review the video and transcript, keeping in mind the inherent uncertainties of forward-looking statements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.